Jeffrey T. Yorio

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity?

Jeffrey T. Yorio, Yang Xie, Jingsheng Yan et al. · Journal of Thoracic Oncology · 2009 · 100 citations · Full text

Health Care Disparity, Health Policy, Cancer Screening +10

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Sara Bedrose, Kevin C. Miller, Lina Altameemi et al. · Journal for ImmunoTherapy of Cancer · 2020 · 53 citations · Full text